Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 8/20 | 1.00 |
| ▸ | NQO2 | P16083 | 2/20 | 0.54 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.53 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1386337 | 0.86 | MTNR1A (0.76) | MTNR1ACA2MEN1MAPTKMT2A | |
| SCHEMBL1567114 | 0.85 | MTNR1A (0.73) | MTNR1ANQO2MTNR1BTRPV1CA12 | |
| SCHEMBL2692928 | 0.84 | MTNR1A (0.73) | MTNR1ANQO2MTNR1BTRPV1CA12 | |
| SCHEMBL29941181 | 0.83 | MTNR1A (0.73) | MTNR1ANQO2MTNR1B | |
| SCHEMBL761446 | 0.83 | MTNR1A (0.73) | MTNR1ANQO2MTNR1B | |
| SCHEMBL6686511 | 0.83 | MTNR1A (0.71) | MTNR1ANQO2MTNR1BTRPV1CA12 | |
| SCHEMBL4036596 | 0.82 | MTNR1A (0.69) | MTNR1ANQO2MTNR1BTRPV1MEN1 | |
| SCHEMBL2608948 | 0.81 | MTNR1A (0.68) | MTNR1ANQO2MTNR1BTRPV1KMT2A | |
| SCHEMBL7898025 | 0.81 | MTNR1A (0.68) | MTNR1ANQO2MTNR1BTRPV1MEN1 | |
| SCHEMBL8065745 | 0.81 | MTNR1A (0.68) | MTNR1ANQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0344425-B1 | N-[[(2,6-disubstituted)phenyl]-N'- arylalkyl] ureas as antihypercholesterolemic and antiatherosclerotic agents | WARNER LAMBERT CO (US) | 1993-12-08 | — | — | EP | claimed |
| JP-6092926-A | — | — | None | — | — | JP | disclosed |
| US-7223755-B2 | Hydroxymorpholinone derivative and medicinal use thereof | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2007-05-29 | — | — | US | disclosed |
| EP-1597256-A1 | N-HETEROCYCLYL-SUBSTITUTED AMINO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PFIZER INC. (US) | 2005-11-23 | — | — | EP | disclosed |
| US-20050176704-A1 | Hydroxymorpholinone derivative and medicinal use thereof | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2005-08-11 | — | — | US | disclosed |
| US-20050101595-A1 | N-containing cycloalkyl-substituted amino-thiazole derivatives and pharmaceutical compositions for inhibiting cell proliferation and methods for their use | PFIZER INC. | 2005-05-12 | — | — | US | disclosed |
| EP-1027043-B1 | BENZODIOXOLE, BENZOFURAN, DIHYDROBENZOFURAN, AND BENZODIOXANE MELATONERGIC AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2004-11-10 | — | — | EP | disclosed |
| WO-2004074283-A1 | N-HETEROCYCLYL-SUBSTITUTED AMINO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PFIZER INC. (US) | 2004-09-02 | — | — | WO | disclosed |
| EP-1027043-A4 | BENZODIOXOLE, BENZOFURAN, DIHYDROBENZOFURAN, AND BENZODIOXANE MELATONERGIC AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2002-02-20 | — | — | EP | disclosed |
| US-6235789-B1 | GLANDULAR DISORDERS; SLEEP DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-05-22 | — | — | US | disclosed |
| EP-0530087-B1 | Naphthylethylurea and naphthylethylthiourea compounds, process for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 1995-05-03 | — | — | EP | disclosed |
| US-5389683-A | Useful in treating or preventing a disorder of the melatoninergic system | ADIR ET COMPAGNIE (FR) | 1995-02-14 | — | — | US | disclosed |
| US-5389683-A | Useful in treating or preventing a disorder of the melatoninergic system | ADIR ET COMPAGNIE (FR) | 1995-02-14 | — | — | US | disclosed |
| US-5385944-A | Naphthylethylureas and naphthylethylthioureas | ADIR ET COMPAGNIE (FR) | 1995-01-31 | — | — | US | disclosed |
| US-5385944-A | Naphthylethylureas and naphthylethylthioureas | ADIR ET COMPAGNIE (FR) | 1995-01-31 | — | — | US | disclosed |
| JP-H0692926-A | NEW NAPHTHYLETHYLUREA AND NAPHTHYLETHYLTHIOUREA, PRODUCTION THEREOF AND MEDICINAL COMPOSITION INCORPORATING THE SAME | ADIR | 1994-04-05 | — | — | JP | disclosed |
| EP-0344425-B1 | N-[[(2,6-disubstituted)phenyl]-N'- arylalkyl] ureas as antihypercholesterolemic and antiatherosclerotic agents | WARNER LAMBERT CO (US) | 1993-12-08 | — | — | EP | disclosed |
| EP-0530087-A1 | Naphthylethylurea and naphthylethylthiourea compounds, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1993-03-03 | — | — | EP | disclosed |
| US-5039801-A | Refluxing in alcoholic solution | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 1991-08-13 | — | — | US | disclosed |
| EP-0344425-A2 | N-[[(2,6-disubstituted)phenyl]-N'- arylalkyl] ureas as antihypercholesterolemic and antiatherosclerotic agents | WARNER-LAMBERT COMPANY (US) | 1989-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176704-A1 | Hydroxymorpholinone derivative and medicinal use thereof | CAPN1, OPRM1, CAPN2 | MTNR1A 221/4885NQO2 2364/4885MTNR1B 233/4885 |
| US-20050101595-A1 | N-containing cycloalkyl-substituted amino-thiazole derivatives and pharmaceutical compositions for inhibiting cell proliferation and methods for their use | CCNI, MKI67, TK1 | MTNR1A 3247/4885NQO2 706/4885MTNR1B 2516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.